^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    SCRI-CARB7H3(s)x19

    i
    Other names: SCRI-CARB7H3(s)x19 , Autologous CD4+ and CD8+ T-cells genetically modified to a bispecific B7H3xCD19 CAR, bispecific B7H3xCD19 CAR, second generation 4-1BBζ B7H3-EGFRt-DHFR(selected) and a second generation 4-1BBζ CD19-Her2tG
    Associations

    News

    Trials
    Company:
    Seattle Children's Hospital
    Drug class:
    CD19-targeted CAR-T immunotherapy, HER2-targeted CAR-T immunotherapy, B7-H3-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    9ms
    STRIvE-01: EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults (clinicaltrials.gov)
    P1, N=44, Recruiting, Seattle Children's Hospital | Trial completion date: Jun 2038 --> Jun 2040 | Trial primary completion date: Jun 2024 --> Jun 2025
    Trial completion date • Trial primary completion date • CAR T-Cell Therapy
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR expression
    |
    EGFR806-specific CAR T-cell therapy • SCRI-CARB7H3(s)x19
    over1year
    STRIvE-02: B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults (clinicaltrials.gov)
    P1, N=68, Active, not recruiting, Seattle Children's Hospital | Recruiting --> Active, not recruiting
    Enrollment closed • CAR T-Cell Therapy
    |
    CD276 (CD276 Molecule)
    |
    CD276 expression • CD19 expression
    |
    Keytruda (pembrolizumab) • SCRI-CARB7H3(s) • SCRI-CARB7H3(s)x19